Safe Biologics
JUNE 12, 2023
Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Unfortunately, the new drug-pricing rules enacted in the Inflation Reduction Act will stymie efforts to develop new cancer treatments.
Safe Biologics
JUNE 12, 2023
Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Unfortunately, the new drug-pricing rules enacted in the Inflation Reduction Act will stymie efforts to develop new cancer treatments.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Safe Biologics
JUNE 12, 2023
Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).
Safe Biologics
JUNE 12, 2023
Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).
European Pharmaceutical Review
JUNE 24, 2022
The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. This obviously presents a huge magnitude of risk for drug developers,” he noted.
pharmaphorum
AUGUST 27, 2020
Regulatory pressures, lengthy drug development times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion.
pharmaphorum
JUNE 2, 2022
While in 2021, orphan drugs made up over half of all the US FDA’s approvals, with the figures in European being similarly high – 19 out of 54 approved new active substances. The report estimates that the orphan drug market will grow twice as fast as the non-orphan market, with a 2021 to 2026 compound annual growth rate of 12%.
Expert insights. Personalized for you.
100 
Let's personalize your content